The Secretary of Foreign Affairs, while participating at President Andres Manuel Lopez Obrador’s daily morning press conference at the Presidential Palace, gave an account of Mexico’s ties with laboratories producing Covid-19 vaccines.
On the list of participants, in which he includes the agreement with Argentina to jointly produce AstraZeneca, Ebrad refers to the Cuban vaccine, which he has already mentioned on other occasions when referring to the commitment to support the production of vaccines among members of the Community of Latin American and Caribbean States (CELAC).
He noted that COFEPRIS on Monday reported that the New Molecules Committee (CMN) gave a favorable opinion on the authorization for emergency use of Abdala.
The vaccine was presented by Neuronic Mexicana S.A. de C.V. in conjunction with the Center for Genetic Engineering and Biotechnology (CIGB) of Cuba.
COFEPRIS explained that the Cuban vaccine is made with the recombinant protein of the SARS-CoV-2 virus receptor binding domain, responsible for the Covid-19 disease. It pointed out that this is the first Latin American Covid-19 vaccine to be authorized by this committee and the favorable technical opinion is an advance in the approval processes necessary to comply with the quality, safety and efficacy requirements, which are indispensable when considering a product, the text clarified.
It indicated that the next step consists of the submission of dossiers by the pharmaceutical company, which will be reviewed by expert personnel from the Health Authorization Commission.